<DOC>
	<DOCNO>NCT00114114</DOCNO>
	<brief_summary>The purpose study determine level testosterone and/or estradiol change bone turnover , body composition , strength , sexual function etc . begin occur . This information may help determine intervene hormone replacement therapy age men .</brief_summary>
	<brief_title>Dose-Response Gonadal Steroids Bone Turnover Men</brief_title>
	<detailed_description>There 3 arm protocol , 5 6 group . In Arm 1 , 240 men age 20-50 receive goserelin acetate ( Zoladex ) plus Androgel ( placebo ) . ( NOTE : ARM 1 IS CLOSED TO RECRUITMENT . In Arm 2 , 200 men age 20-50 receive goserelin acetate ( Zoladex ) plus Androgel ( placebo ) plus anastrazole ( Arimidex ) . NOTE : ARM 2 IS CLOSED TO RECRUITMENT.. In Arm 3 , 240 men age 60 75 receive goserelin acetate ( Zoladex ) plus Androgel ( placebo ) . ( Arm 3 recruiting ) . Subjects screen MGH General Clinical Research Center ( GCRC ) . After obtain informed consent screening procedure , subject undergo complete history physical examination . If exclusionary finding note history physical examination , blood drawn measure hemoglobin , routine chemistry ( include serum calcium , liver function test , creatinine ) , serum level PTH , 25-OH vitamin D , TSH , T , PSA . For Arm 3 , subject successfully screen randomly assign computer one 6 group . All subject receive GnRH agonist goserelin acetate ( Zoladex ; AstraZeneca , Wilmington , DE ) 3.6 mg sc every 4 week 16 week . Subjects Group 1 receive goserelin acetate placebo Androgel . Subjects Groups 2-5 receive varying dose Androgel . Subjects Group 6 receive double placebo ( e.g . placebo Zoladex placebo Androgel ) . Subjects blind respect group assignment . Dietary calcium intake assess research dietitian adjustment make diet supplement calcium intake 1000 1200 mg/day . Subjects see GCRC 4 week interval 16 week ( 0 , 4 , 8 , 12 , 16 week ) . At visit , compliance Androgel ' assess review medication diary . A standardized series question pose subject assess potential side effect study drug . Subjects receive Androgel ' give new 4 week supply medication ( except week 16 ) . A fasting blood second void urine sample collect . After blood urine sample obtain , subject give goserelin injection . The blood urine test list well anthropometric measure , questionnaire perform visit . DXA , CT scan , strength assessment perform 0 16 week . Subjects discontinue participation week 8 ask willing early discontinuation visit procedure normally do week 16 perform . The following measure assess : - Routine chemistry PSA ( safety assessment ) - Bone turnover use blood urine test - Hormones - Lipids - Body composition - Strength - Symptoms hypogonadism - Bone mineral density bone microarchitecture</detailed_description>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Healthy men age 20 50 year 60 75 . NOTE : RECRUITMENT OF MEN AGE 2050 IS COMPLETE . History significant cardiac , renal , pulmonary , hepatic , benign prostatic hyperplasia , malignant disease , current alcohol illicit drug abuse , major psychiatric disorder . Current diagnose disorder know affect bone metabolism include hyperthyroidism , hyperparathyroidism , osteomalacia , Paget 's disease . Current use medication know affect bone metabolism include estrogen , androgen , antiestrogens , bisphosphonates , calcitonin , fluoride , oral inhaled glucocorticoid , suppressive dos thyroxine , lithium , pharmacological dos vitamin D ( great 2000 IU/day ) , anticonvulsant . Cognitive intellectual impairment precludes complete understand study protocol . History deep vein thrombosis , pulmonary embolism , clot disorder . Serum 25OH vitamin D &lt; 15 ng/mL Serum PTH &lt; 10 &gt; 65 pg/mL Serum TSH &lt; 0.5 &gt; 5.0 U/L Serum calcium &gt; 10.6 mg/dL Serum creatinine &gt; 2 mg/dL Serum AST ALT &gt; 2x upper limit normal Serum bilirubin &gt; 2 mg/dL Serum alkaline phosphatase &gt; 150 U/L Plasma hemoglobin &lt; 11 gm/dL Hematocrit &gt; 50 Fracture within last 6 month . Serum testosterone level &lt; 270 &gt; 1070 ng/dL Serum PSA level &gt; 4 ug/L . International Prostate Symptom Score ( IPSS ) &gt; 19 Systolic blood pressure &gt; 160 diastolic blood pressure &gt; 95 Framingham risk score great equal 20 Difficulty walk 2 block</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Bone turnover</keyword>
	<keyword>Aging</keyword>
	<keyword>Body composition</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Sexual function</keyword>
</DOC>